- Home
- BEAM
as 04-18-2025 1:31pm EST
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $50.50 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.58 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.53 - $35.25 | Next Earning Date: | 05-06-2025 |
| Revenue: | $63,518,000 | Revenue Growth: | -83.18% |
| Revenue Growth (this year): | -4.02% | Revenue Growth (next year): | 6.32% |
Stock Insider Trading Activity of Beam Therapeutics Inc. (BEAM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Evans John M. | BEAM | CEO | Apr 1 '25 | Sell | $18.35 | 30,663 | $562,684.45 | 986,249 | |
| Ciaramella Giuseppe | BEAM | President | Apr 1 '25 | Sell | $18.35 | 7,434 | $136,418.36 | 190,216 | |
| Bellon Christine | BEAM | Chief Legal Officer | Apr 1 '25 | Sell | $18.35 | 5,674 | $104,121.87 | 117,294 | |
| Cavanagh Bethany J | BEAM | SVP, Finance and Treasurer | Apr 1 '25 | Sell | $18.35 | 3,015 | $55,330.07 | 44,512 | |
| Cavanagh Bethany J | BEAM | SVP, Finance and Treasurer | Feb 18 '25 | Sell | $35.00 | 6,287 | $220,045.00 | 44,512 | |
| Bellon Christine | BEAM | Chief Legal Officer | Feb 14 '25 | Sell | $34.00 | 10,000 | $340,000.00 | 117,294 | |
| Evans John M. | BEAM | CEO | Jan 30 '25 | Sell | $27.01 | 30,000 | $802,483.82 | 986,249 |
Latest Beam Therapeutics Inc. News
BEAM Breaking Stock News: Dive into BEAM Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures
Zacks
9 days ago
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?
Benzinga
12 days ago
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease
GlobeNewswire
14 days ago
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress
MT Newswires
16 days ago
RBC Cuts Price Target on Beam Therapeutics to $20 From $26, Keeps Sector Perform, Speculative Risk
Insider Monkey
18 days ago
Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?
TipRanks
18 days ago
Biotech stocks slide as Marks resignation seen being negative for sector
The Wall Street Journal
19 days ago
Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street
Compare BEAM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BEAM Beam Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.